Pirfenidone in RA-ILD, TRAIL-1 study. Long-awaited. Early termination due to COVID led to under-powering. Slowed decline in FVC, especially in UIP pattern. Seemed to have less adverse events than we see with nintedanib. Abstr#L10 #ACR21 @RheumNow https://t.co/sYRDhG3u4y